Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study

The durability of antibody responses induced by the three-dose of CoronaVac vaccination, especially against SARS-CoV-2 Omicron subvariants, remains unclear. Here in our study, 160 plasma samples from 32 healthy individuals who received three doses of CoronaVac were longitudinally tracked for a perio...

Full description

Bibliographic Details
Main Authors:	Cheng Cao, Qin Guo, Yaping Dai, Junfeng Jiang, Min Liu, Tuo Ji, Pengcheng Zhou, Fang Gong
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-08-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	coronavac covid-19 vaccine neutralizing antibodies sars-cov-2 omicron subvariants
Online Access:	http://dx.doi.org/10.1080/21645515.2023.2242217

Similar Items

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
by: Xue-Jun Wang, et al.
Published: (2022-12-01)

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
by: Suvichada Assawakosri, et al.
Published: (2024-01-01)

Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination
by: Jianhua Li, et al.
Published: (2022-12-01)

Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay
by: Mako Toyoda, et al.
Published: (2023-08-01)

Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants
by: Yaning Li, et al.
Published: (2023-06-01)

SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients
by: Yuxin Chen, et al.
Published: (2024-04-01)

The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population
by: Jéssica Pires Farias, et al.
Published: (2023-12-01)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
by: Hanzhong Ke, et al.
Published: (2022-09-01)

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
by: Wei Zhao, et al.
Published: (2022-06-01)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
by: Cheng Cao, et al.
Published: (2023-10-01)

Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
by: Panke Qu, et al.
Published: (2023-02-01)

Body Mass Index, Age, and Gender Affect CoronaVac Vaccine Antibody Response
by: Ayfer ÇOLAK, et al.
Published: (2022-08-01)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
by: Samar Samoud, et al.
Published: (2023-08-01)

Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China
by: Benchen Rao, et al.
Published: (2024-12-01)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
by: Chiranjib Chakraborty, et al.
Published: (2023-03-01)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022-12-01)

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
by: Bárbara M. Schultz, et al.
Published: (2022-08-01)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
by: Srijan Chatterjee, et al.
Published: (2023-06-01)

The Early-Term Adverse Effects in Healthcare Personnel after CoronaVac Vaccination
by: Mehmet Kabak, et al.
Published: (2022-03-01)

Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells
by: Revansiddha H. Katte, et al.
Published: (2024-03-01)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
by: Lu Zhang, et al.
Published: (2022-09-01)

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
by: Samuel M.S. Cheng, et al.
Published: (2024-03-01)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2022-12-01)

Humoral Immune Response to CoronaVac in Turkish Adults
by: Yasemin Cosgun, et al.
Published: (2023-01-01)

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
by: Zhujun Jiang, et al.
Published: (2022-05-01)

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study
by: Yuxiao Wang, et al.
Published: (2023-03-01)

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
by: Alejandro Escobar, et al.
Published: (2022-01-01)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
by: Ruiqi Zhang, et al.
Published: (2022-04-01)

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines
by: Lu Lu, et al.
Published: (2022-05-01)

Sobre a eficácia da CoronaVac no Twitter: conversações e aspectos políticos
by: Carina Luisa Ochi Flexor, et al.
Published: (2022-12-01)

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
by: Sutima Luangdilok, et al.
Published: (2022-09-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023-01-01)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
by: Okesanya Olalekan John, B'MLS, et al.
Published: (2023-12-01)

Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
by: Jianliang Huang, et al.
Published: (2023-10-01)

Vitamin D levels and clinical outcomes of SARS-CoV-2 Omicron subvariant BA.2 in children: A longitudinal cohort study
by: Denggao Peng, et al.
Published: (2022-07-01)

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
by: Thiago Cerqueira-Silva, et al.
Published: (2022-02-01)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
by: Yun Shan Goh, et al.
Published: (2022-01-01)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
by: Priscilla Ramos Costa, et al.
Published: (2022-10-01)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
by: Shuai Xia, et al.
Published: (2023-12-01)